Yuichiro Ohe

Yuichiro Ohe

UNVERIFIED PROFILE

Are you Yuichiro Ohe?   Register this Author

Register author
Yuichiro Ohe

Yuichiro Ohe

Publications by authors named "Yuichiro Ohe"

Are you Yuichiro Ohe?   Register this Author

100Publications

2800Reads

39Profile Views

Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.

N Engl J Med 2020 01 21;382(1):41-50. Epub 2019 Nov 21.

From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.S.R.); the Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium (J.V.); the Thoracic Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif (D.P., J.-C.S.), and University Paris Sud, Orsay (J.-C.S.) - both in France; the Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and the Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju (K.H.L.) - both in South Korea; the Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.E.G.); the Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka (F.I.), and the Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka (T.K.) - all in Japan; Pulmonary Hospital of Tongji University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun (Y.C.) - both in China; the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), and the Oncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai (B.C.) - both in Thailand; Kent Oncology Centre, Maidstone Hospital, and Tunbridge Wells NHS Trust, Maidstone (R.S.), and Late Oncology Statistics (A.T., R.H.) and Oncology Research and Development (M.S., Y.R.), AstraZeneca, Cambridge - both in the United Kingdom; Hospital Regional Universitario Málaga, Instituto de Investigación Biomédica de Málaga, Malaga, Spain (M.C.); William Osler Health System, University of Toronto, Toronto (P.C.); the Department of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, Parma, Italy (M.T.); the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan (M.-C.L.); and Early Oncology Research and Development, AstraZeneca, Gaithersburg, MD (J.-C.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1913662DOI Listing
January 2020

Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.

Immunotherapy 2019 10 26;11(15):1337-1351. Epub 2019 Sep 26.

Biosimilars Business Unit, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2019-0125DOI Listing
October 2019

Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient.

Jpn J Clin Oncol 2019 Aug;49(8):793-794

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/article/49/8/793/5514165
Publisher Site
http://dx.doi.org/10.1093/jjco/hyz087DOI Listing
August 2019

Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology.

Jpn J Clin Oncol 2019 Jun;49(6):559-566

Department of Pathology and Clinical Laboratories, Pathology Division, National Cancer Center Hospital, 5-1-1, Tsukiji Chou-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz032DOI Listing
June 2019

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.

Eur J Cancer 2019 May 13;113:78-86. Epub 2019 Apr 13.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.03.012DOI Listing
May 2019

Next-Generation Sequencer Analysis of Pulmonary Pleomorphic Carcinoma With a CD74-ROS1 Fusion Successfully Treated With Crizotinib.

J Thorac Oncol 2019 05;14(5):e106-e108

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Cancer Medicine, Jikei University Graduate School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.005DOI Listing
May 2019

Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.

Cancer Sci 2019 Apr 21;110(4):1401-1407. Epub 2019 Mar 21.

Third Department of Internal Medicine, Division of Pulmonary Medicine & Medical Oncology, Wakayama Medical University, Wakayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447840PMC
April 2019

Patient-reported outcomes in a phase II study of alectinib.

Authors:
Yuichiro Ohe

ESMO Open 2018 15;3(5):e000412. Epub 2018 Jul 15.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069919PMC
July 2018

Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer.

Oncologist 2018 04 6;23(4):489-495. Epub 2017 Dec 6.

Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City Graduate School of Medical Science, Nagoya, Aichi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896705PMC
April 2018

The first case of SMARCB1 (INI1) - deficient squamous cell carcinoma of the pleura: a case report.

BMC Cancer 2018 04 7;18(1):398. Epub 2018 Apr 7.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4321-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889546PMC
April 2018

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 03 25;36(9):841-849. Epub 2017 Aug 25.

Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.7576
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.7576DOI Listing
March 2018

Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer.

Cancer Chemother Pharmacol 2018 03 31;81(3):565-572. Epub 2018 Jan 31.

Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3530-yDOI Listing
March 2018

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

Lung Cancer 2018 03 9;117:14-19. Epub 2018 Jan 9.

Department of Medical Oncology, Izumi Municipal Hospital, 4-10-10 Fuchu, Izumi, 594-0071, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.01.005DOI Listing
March 2018

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

N Engl J Med 2018 01 18;378(2):113-125. Epub 2017 Nov 18.

From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju (K.H.L.), the Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and the Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.E.G.); the Department of Oncology, University College London Hospitals Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all in the United Kingdom; and Emory University School of Medicine, Winship Cancer Institute, Atlanta (S.S.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713137DOI Listing
January 2018

The genomic and epigenomic landscape in thymic carcinoma.

Carcinogenesis 2017 10;38(11):1084-1091

Division of Genome Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgx094DOI Listing
October 2017

welcomes the association with the Japanese Society of Medical Oncology (JSMO).

ESMO Open 2017 4;2(3):e000240. Epub 2017 Aug 4.

Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2017-000240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703397PMC
August 2017

Efficacy and safety of osimertinib in a Japanese compassionate use program.

Jpn J Clin Oncol 2017 Jul;47(7):625-629

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyx050DOI Listing
July 2017

Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.

Clin Ther 2017 Jun 18;39(6):1146-1160. Epub 2017 May 18.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2017.04.010DOI Listing
June 2017

PD-L1 expression in neuroendocrine tumors of the lung.

Lung Cancer 2017 06 24;108:115-120. Epub 2017 Mar 24.

Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.03.006DOI Listing
June 2017

Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.

Lung Cancer 2017 06 1;108:66-71. Epub 2017 Mar 1.

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.02.018DOI Listing
June 2017

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.

J Clin Oncol 2017 May 15;35(14):1515-1521. Epub 2017 Mar 15.

Tomohide Tamura, St Luke's International Hospital; Yuichiro Ohe, National Cancer Center Hospital; Hiroshi Kuriki, Tadashi Shimada, and Tomohiro Tanaka, Chugai Pharmaceutical; Kengo Takeuchi, Japanese Foundation for Cancer Research; Makoto Nishio, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo; Katsuyuki Kiura, Okayama University Hospital, Okayama; Takashi Seto, National Kyusyu Cancer Center, Fukuoka; Kazuhiko Nakagawa, Kindai University, Osaka-Sayama; Makoto Maemondo, Miyagi Cancer Center, Natori; Akira Inoue, Tohoku University, Sendai; Toyoaki Hida, Aichi Cancer Center, Nagoya; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Masao Harada, Hokkaido Cancer Center, Sapporo; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; and Haruyasu Murakami, Shizuoka Cancer Center, Shizuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.5749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455704PMC
May 2017

Treatment of lung cancer using immune checkpoint inhibitors.

Nihon Rinsho 2017 02;75(2):221-228

View Article

Download full-text PDF

Source
February 2017

Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy.

Clin Lung Cancer 2016 11 16;17(6):581-587. Epub 2016 Jun 16.

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.05.022DOI Listing
November 2016

Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.

Clin Lung Cancer 2016 09 5;17(5):412-418. Epub 2016 Feb 5.

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Juntendo University Graduate School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.01.006DOI Listing
September 2016

Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.

Asia Pac J Clin Oncol 2016 Sep 7;12(3):259-64. Epub 2016 Mar 7.

Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12485DOI Listing
September 2016

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Authors:
Christian Dittrich Michael Kosty Svetlana Jezdic Doug Pyle Rossana Berardi Jonas Bergh Nagi El-Saghir Jean-Pierre Lotz Pia Österlund Nicholas Pavlidis Gunta Purkalne Ahmad Awada Susana Banerjee Smita Bhatia Jan Bogaerts Jan Buckner Fatima Cardoso Paolo Casali Edward Chu Julia Lee Close Bertrand Coiffier Roisin Connolly Sarah Coupland Luigi De Petris Maria De Santis Elisabeth G E de Vries Don S Dizon Jennifer Duff Linda R Duska Alexandru Eniu Marc Ernstoff Enriqueta Felip Martin F Fey Jill Gilbert Nicolas Girard Andor W J M Glaudemans Priya K Gopalan Axel Grothey Stephen M Hahn Diana Hanna Christian Herold Jørn Herrstedt Krisztian Homicsko Dennie V Jones Lorenz Jost Ulrich Keilholz Saad Khan Alexander Kiss Claus-Henning Köhne Rainer Kunstfeld Heinz-Josef Lenz Stuart Lichtman Lisa Licitra Thomas Lion Saskia Litière Lifang Liu Patrick J Loehrer Merry Jennifer Markham Ben Markman Marius Mayerhoefer Johannes G Meran Olivier Michielin Elizabeth Charlotte Moser Giannis Mountzios Timothy Moynihan Torsten Nielsen Yuichiro Ohe Kjell Öberg Antonio Palumbo Fedro Alessandro Peccatori Michael Pfeilstöcker Chandrajit Raut Scot C Remick Mark Robson Piotr Rutkowski Roberto Salgado Lidia Schapira Eva Schernhammer Martin Schlumberger Hans-Joachim Schmoll Lowell Schnipper Cristiana Sessa Charles L Shapiro Julie Steele Cora N Sternberg Friedrich Stiefel Florian Strasser Roger Stupp Richard Sullivan Josep Tabernero Luzia Travado Marcel Verheij Emile Voest Everett Vokes Jamie Von Roenn Jeffrey S Weber Hans Wildiers Yosef Yarden

ESMO Open 2016 29;1(5):e000097. Epub 2016 Sep 29.

Department of General Medical Oncology , University Hospitals Leuven , Leuven , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070299PMC
September 2016

The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor.

Neuropeptides 2016 Aug 22;58:93-101. Epub 2015 Dec 22.

Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Division of Supportive Care Research, National Cancer Center Exploratory Oncology Research and Clinical Trial Center Research, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center, 5-1-1 Tsukiji, Tokyo 104-0045, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.npep.2015.12.010DOI Listing
August 2016

Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

Int J Radiat Oncol Biol Phys 2016 Jan 26;94(1):155-162. Epub 2015 Sep 26.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.09.026DOI Listing
January 2016

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.

Lung Cancer 2015 Dec 9;90(3):477-83. Epub 2015 Oct 9.

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.09.025DOI Listing
December 2015